DCE-MRI Study Abstract Selected by ASCO
ACR Image Metrix
™ is pleased to announce that the DCE-MRI study, as commissioned by
Bionomics Ltd.
, was submitted as an abstract by Bionomics to the American Society of Clinical Oncology (ASCO) and has been accepted to be presented as a part of the scientific program during the general poster session at the
ASCO Annual Meeting
, which will take place June 4-8, 2010, in Chicago, Illinois, at McCormick Place.
As a drug discovery and development organization focusing on new treatments for cancer and serious disorders of the central nervous system, Bionomics selected ACR Image Metrix to perform the imaging components of this study.
“Their extensive experience in the utilization of novel imaging techniques to serve as biomarkers and history of partnering with regulatory agencies to develop standards for imaging acquisition, data normalization, data extraction and the assessment of variability made the selection of ACR Image Metrix as our imaging CRO appropriate for this project,” stated Bionomics Vice President of Discovery Research, Gabriel Kremmidiotis, Ph.D.
The completion of this Phase I clinical trial, which involved
MRI (DCE-MRI)
quantitative analysis, was a two-stage dose escalation design involving Bionomics’ BNC 105P-001, a novel vascular disrupting agent staged in patients with advanced solid tumors.
“Teaming up with Bionomics to complete this study turned out to be a success and we are pleased with the results. This is a major milestone for ACR Image Metrix in our ability to conduct novel imaging for both pharmaceutical and biotech companies,” stated General Manager of ACR Image Metrix, Michael J. Morales.
ACR Image Metrix will also be exhibiting at the ASCO Annual Meeting, Booth 19097.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
